Source: Cancer Biomarkers. Unidade: FMRP
Subjects: BIOMARCADORES, NEOPLASIAS DO COLON, METÁSTASE NEOPLÁSICA, CÉLULAS-TRONCO, MOLÉCULAS DE ADESÃO CELULAR
ABNT
RIBEIRO, Karen Bento et al. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer. Cancer Biomarkers, v. 16, n. 4, p. 513-521, 2016Tradução . . Disponível em: https://doi.org/10.3233/CBM-160592. Acesso em: 01 maio 2024.APA
Ribeiro, K. B., Zanetti, J. da S., Ribeiro-Silva, A., Rapatoni, L., Oliveira, H. F. de, Tirapelli, D. P. da C., et al. (2016). KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer. Cancer Biomarkers, 16( 4), 513-521. doi:10.3233/CBM-160592NLM
Ribeiro KB, Zanetti J da S, Ribeiro-Silva A, Rapatoni L, Oliveira HF de, Tirapelli DP da C, Garcia SB, Féres O, Rocha JJR da, Peria FM. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer [Internet]. Cancer Biomarkers. 2016 ; 16( 4): 513-521.[citado 2024 maio 01 ] Available from: https://doi.org/10.3233/CBM-160592Vancouver
Ribeiro KB, Zanetti J da S, Ribeiro-Silva A, Rapatoni L, Oliveira HF de, Tirapelli DP da C, Garcia SB, Féres O, Rocha JJR da, Peria FM. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer [Internet]. Cancer Biomarkers. 2016 ; 16( 4): 513-521.[citado 2024 maio 01 ] Available from: https://doi.org/10.3233/CBM-160592